Our new research paper titled “Effective and Targeted Human Orthotopic Glioblastoma Xenografts Therapy via a Multifunctional Biomimetic Nanomedicine” was recently accepted for publication on Advanced Materials with no comments. In this article, our team has developed erythrocyte membrane coated with biomimetic nanomedicine for the use of efficient and safe glioblastoma targeted therapy. This new approach potentially solved several pressing obstacles faced by traditional nanomedicine, such as poor biocompatibility, short blood circulation time, limited blood brain barrier (BBB) crossing ability, systemic side effect and low drug availability. This multifunctional biomimetic nanomedicine platform is promised as a novel treatment for clinical brain related diseases, including glioblastoma.  

Advanced Materials is an international top peer-reviewed journal with a current IF of 21.95.

The main body of this work was completed here in our center, in collaboration with Prof. Roger Chung’s lab in Macquarie University as well as Dr. Geng’s lab in Sichuan University. Dr. Zou and Ph.D. candidate Yanjie Liu are shared first authors, and Prof. Shi and Prof. Zheng as co-corresponding authors.

This project was supported by National Natural Science Foundation of China (NSFC 31600809, 31640027, 51803049 and U1604177), National Postdoctoral Program for Innovative Talents (BX201700070), the National Health and Medical Research Council (NHMRC) dementia fellowship (APP1111611), China Postdoctoral Science Foundation (2017M620299), the National Key Technologies R&D program of China (2018YFA0209800), Macquarie University Research Fellowship and the Program of China’s 1000-talents Plan.